Vitiligo: etiology, pathogenesis and therapy

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Vitiligo is an autoimmune disease. The prevalence of the disease is 0.5% of the population. The main etiological factor is genetic defect of melanogenesis enzymatic system. The article is a review. The current data on the pathogenesis, classification and treatment of vitiligo are presented. Existing therapies mainly have moderate efficacy. The principal methods of treatment are ultraviolet therapy, laser therapy, topical corticosteroids and calcineurin inhibitors.

Full Text

Restricted Access

About the authors

Larisa S. Kruglova

Moscow Scientific and Practical Center of Dermatology, Venereology and Cosmetology, Department of Health, Moscow

Email: kruglovals@mail.ru
Moscow, 107564, Russian Federation
MD, PhD, Professor, Moscow Scientific and Practical Center of Dermatology, Venereology and Cosmetology, Department of Health of Moscow

References

  1. Taieb A., Picardo M. Epidemiology, definitions and classification. In: Taieb A., Picardo M., eds. Vitiligo. Berlin, Heidelberg: Springer; 2010: 13-24.
  2. Taieb A., Alomar A., Bohm M., Dell‘Anna M.L., A. De Pase A., Eleftheriadou V., et al.; Vitiligo European Task Force (VETF); European Academy of Dermatology and Venereology (EADV); Union Europeenne des Medecins Specialistes (UEMS) Guidelines for the management of vitiligo: the European Dermatology Forum consensus.. Br. J. Dermatol. 2013; 168(1): 5-19. doi: 10.1111/j.1365-2133.2012.11197.x.
  3. Ezzedine K., Lim H.W., Suzuki T., Katayama I., Hamzavi I., Lan C.C., et al.; Vitiligo Global Issue Consensus Conference Panelists. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012; 25(3): E1-13. doi: 10.1111/j.1755-148X.2012.00997.x.
  4. Whitton M.E., Pinart M., Batchelor J., Lushey C., Leonardi-Bee J., González U. Interventions for vitiligo. Cochrane Database Syst. Rev. 2010; (1): CD003263. doi: 10.1002/14651858.CD003263.pub4.
  5. Ho N., Pope E., Weinstein M., Greenberg S., Webster C., Krafchik B.R. A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0.1% vs clobetasol propionate 0.05% in childhood vitiligo. Br. J. Dermatol. 2011; 165(3): 626-32. doi: 10.1111/j.1365-2133.2011.10351.x.
  6. Njoo M.D., Spuls P.I., Bos J.D., Westerhof W., Bossuyt P.M. Nonsurgical repigmentation therapies in vitiligo: meta-analysis of the literature. Arch. Dermatol. 1998; 134(12): 1532-40.
  7. Jin Y., Mailloux C.M., Gowan K., Riccardi S.L., LaBerge G., Bennett D.C., et al. NALP1 in vitiligo-associated multiple autoimmune disease. N. Engl. J. Med. 2007; 356(12): 1216-25.
  8. Lan C.C., Wu C.S., Chen G.S., Yu H.S. FK506 (tacrolimus) and endothelin combined treatment induces mobility of melanoblasts: new insights into follicular vitiligo repigmentation induced by topical tacrolimus on sunexposed skin. Br. J. Dermatol. 2011; 164(3): 490-6. doi: 10.1111/j.1365-2133.2010.10113.x.
  9. Dawid M., Veensalu M., Grassberger M., Wolff K. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, doubleblind, vehicle-controlled study. J. Dtsch. Dermatol. Ges. 2006; 4(11): 942-6.
  10. Lepe V., Moncada B., Castanedo-Cazares J.P., Torres-Alvarez M.B., Ortiz C.A., Torres-Rubalcava A.B. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch. Dermatol. 2003; 139(5): 581-5.
  11. Coskun B., Saral Y., Turgut D. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur. J. Dermatol. 2005; 15(2): 88-91.
  12. Ostovari N., Passeron T., Lacour J.P., Ortonne J.P. Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. Arch. Dermatol. 2006; 142(3): 252-3.
  13. Kawalek A.Z., Spencer J.M., Phelps R.G. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol. Surg. 2004; 30(2, Pt 1): 130-5.
  14. Asawanonda P., Kijluakiat J., Korkij W., Sindhupak W. Targeted broadband ultraviolet B phototherapy produces similar responses to targeted narrowband ultraviolet B phototherapy for vitiligo: a randomized, double-blind study. Acta Dermatol. Venereol. 2008; 88(4): 376-81.
  15. Bhatnagar A., Kanwar A.J., Parsad D., De D.Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: an open prospective study. J. Eur. Acad. Dermatol. Venereol. 2007; 21(5): 638-42.
  16. Yones S.S., Palmer R.A., Garibaldinos T.M., Hawk J.L. Randomized doubleblind trial of treatment of vitiligo: efficacy psoralen UVA therapy vs narrowband UVB therapy. Arch. Dermatol. 2007; 143(5): 578-84.
  17. Sassi F., Cazzaniga S., Tessari G., Chatenoud L., Reseghetti A., Marchesi L., et al. Randomized controlled trial comparing the effectiveness of 308 nm excimer laser alone or in combination with topical hydrocortisone 17-butyrate cream in the treatment of vitiligo of the face and neck. Br. J. Dermatol. 2008; 159(5): 1186-91. doi: 10.1111/j.1365-2133.2008.08793.x.
  18. Passeron T., Ostovari N., Zakaria W., Fontas E., Larrouy J.C., Lacour J.P, Ortonne J.P. Topical tacrolimus and the 308-nm excimer laser: asynergistic combination for the treatment of vitiligo. Arch. Dermatol. 2004; 140(9): 1065-9.
  19. Пинсон И.Я., Олисова О.Ю., Башлакова К.А. Сравнение клинической эффективности эксимерных лампы и лазера при витилиго: рандомизированное исследование. Российский журнал кожных и венерических болезней. 2015; 18(5): 28-33.
  20. Singh A., Kanwar A.J., Parsad D., Mahajan R. Randomized controlled study to evaluate the effectiveness of dexamethasone oral minipulse therapy versus oral minocycline in patients with active vitiligo vulgaris. Indian J. Dermatol. Venereol. Leprol. 2014; 80(1): 29-35. doi: 10.4103/0378-6323.125479.
  21. Rath N., Kar H.K., Sabhnani S. An open labeled, comparative clinical study on efficacy and tolerability of oral minipulse of steroid (OMP) alone, OMP with PUVA and broad/narrow band UVB phototherapy in progressive vitiligo. Indian J. Dermatol. Venereol. Leprol. 2008; 74(4): 357-60.
  22. Radakovic-Fijan S., Furnsinn-Fridl A.M., Honigsmann H., Tanew A. Oral dexamethasone pulse treatment for vitiligo. J. Am. Acad. Dermatol. 2001; 44 (5): 814-7.
  23. Lahiri K., Chatterjee M., Sarkar R., eds. Pigmentary Disorders: A Comprehensive Compendium. New Delhi: Jaypee Brothers Medical Publishers; 2014.
  24. Gupta A.K., Ellis C.N., Nickoloff B.J., Goldfarb M.T., Ho V.C., Rocher L.L., et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch. Dermatol. 1990; 126(3): 339-50.
  25. Dell’Anna M.L., Picardo M. A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. Pigment. Cell Res. 2006; 19(5): 406-11.
  26. Parsad D., Gupta S.; IADVL Dermatosurgery Task Force. Standard guidelines of care for vitiligo surgery. Indian J. Dermatol. Venereol. Leprol. 2008; 74(Suppl): S37-45.
  27. Lee D.Y., Choi S.C. A proposal for the treatment guideline in segmental vitiligo. Int. J. Dermatol. 2012; 51(10): 1274-5. doi: 10.1111/j.1365-4632.2010.04694.x.

Statistics

Views

Abstract - 46

PDF (Russian) - 0

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


Copyright (c) 2016 Kruglova L.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies